Track topics on Twitter Track topics that are important to you
Gamma Secretase EC 3.4.23. Pipeline Review, H2 2018
Gamma Secretase EC 3.4.23. pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Gamma Secretase EC 3.4.23. Pipeline Review, H2 2018, outlays comprehensive information on the Gamma Secretase EC 3.4.23. targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Gamma Secretase EC 3.4.23. Gamma secretase is a multisubunit protease complex, itself an integral membrane protein, that cleaves singlepass transmembrane proteins at residues within the transmembrane domain. The most wellknown substrate of gamma secretase is amyloid precursor protein, when cleaved by both gamma and beta secretase, produces a short 3942 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients.
Gamma secretase is also critical in the related processing of the Notch protein. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 9 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Ear Nose Throat Disorders, Cardiovascular and Non Malignant Disorders which include indications Alzheimer's Disease, Hearing Disorders, Benign Tumor, Brain Cancer, Burkitt Lymphoma, Congestive Heart Failure Heart Failure, Glioblastoma Multiforme GBM, Leukemias, Medulloblastoma, Metastatic Breast Cancer, Prostate Cancer and Soft Tissue Sarcoma.
Furthermore, this report also reviews key players involved in Gamma Secretase EC 3.4.23. targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
The report provides a snapshot of the global therapeutic landscape for Gamma Secretase EC 3.4.23.
The report reviews Gamma Secretase EC 3.4.23. targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Gamma Secretase EC 3.4.23. targeted therapeutics and enlists all their major and minor projects
The report assesses Gamma Secretase EC 3.4.23. targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Gamma Secretase EC 3.4.23. targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Gamma Secretase EC 3.4.23.
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Gamma Secretase EC 3.4.23. development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeNEXT ARTICLE
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase 'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...